{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-073484","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.425767+00:00","generated_at":"2026-06-01T03:14:12.806363+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024","bullets":["Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.","Base salary $450k/year; option for 60k shares and 30k restricted stock grant.","Eligible for annual cash bonus up to 35% of base salary and $10k signing bonus.","Previously founded BioCentriq, a CDMO acquired for $73M by GC Holdings.","Appointment supports operational readiness for NurOwn® Phase 3b ALS study."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-073484","json":"https://secwatch.observer/filing/0001104659-24-073484.json","markdown":"https://secwatch.observer/filing/0001104659-24-073484.md","text":"https://secwatch.observer/filing/0001104659-24-073484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/tm2417625d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:14:12.806363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9c465f3ab","claim":"Hartoun Hartounian was appointed as Executive Vice President and Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..","evidence_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001671933-26-000063","ticker":"TTD","company_name":"Trade Desk, Inc.","filed_at":"2026-06-01T20:35:28+00:00","headline":"The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001671933-26-000063","json":"https://secwatch.observer/filing/0001671933-26-000063.json","markdown":"https://secwatch.observer/filing/0001671933-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/ttd-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0001193125-26-251467","ticker":"PENG","company_name":"Penguin Solutions, Inc.","filed_at":"2026-06-01T20:17:28+00:00","headline":"Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251467","json":"https://secwatch.observer/filing/0001193125-26-251467.json","markdown":"https://secwatch.observer/filing/0001193125-26-251467.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/d104493d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm"}},{"accession":"0002064307-26-000007","ticker":"LOGC","company_name":"ContextLogic Holdings Inc.","filed_at":"2026-06-01T20:15:17+00:00","headline":"ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002064307-26-000007","json":"https://secwatch.observer/filing/0002064307-26-000007.json","markdown":"https://secwatch.observer/filing/0002064307-26-000007.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/logc-20260529.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2064307/000206430726000007/0002064307-26-000007-index.htm"}},{"accession":"0001104659-26-068929","ticker":"VMI","company_name":"VALMONT INDUSTRIES INC","filed_at":"2026-06-01T20:15:13+00:00","headline":"Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068929","json":"https://secwatch.observer/filing/0001104659-26-068929.json","markdown":"https://secwatch.observer/filing/0001104659-26-068929.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/vmi-20260526x8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm","comparable_excerpt":"Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/102729/000110465926068929/0001104659-26-068929-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}